Dimensional Fund Advisors LP Has $23.49 Million Holdings in CRISPR Therapeutics AG $CRSP

Dimensional Fund Advisors LP decreased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 45.5% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 494,218 shares of the company’s stock after selling 412,889 shares during the quarter. Dimensional Fund Advisors LP’s holdings in CRISPR Therapeutics were worth $23,488,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 7.5% during the 4th quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock worth $551,777,000 after acquiring an additional 735,084 shares during the last quarter. Orbis Allan Gray Ltd lifted its holdings in CRISPR Therapeutics by 19.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 5,950,145 shares of the company’s stock valued at $312,026,000 after purchasing an additional 968,060 shares during the last quarter. Capital International Investors lifted its holdings in CRISPR Therapeutics by 4.3% during the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock valued at $309,016,000 after purchasing an additional 243,487 shares during the last quarter. State Street Corp boosted its position in CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after purchasing an additional 859,334 shares during the period. Finally, GSK plc bought a new position in CRISPR Therapeutics during the fourth quarter worth $168,890,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CRSP shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, July 8th. Citigroup upped their price target on shares of CRISPR Therapeutics from $82.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday. Citizens Jmp reissued a “market outperform” rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a report on Monday, July 6th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $55.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $68.06.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $51.64 on Friday. The company has a quick ratio of 17.96, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $4.99 billion, a P/E ratio of -10.85 and a beta of 1.74. CRISPR Therapeutics AG has a 12-month low of $44.12 and a 12-month high of $78.48. The firm has a 50-day moving average price of $52.42 and a two-hundred day moving average price of $52.30.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The business had revenue of $10.18 million for the quarter. Analysts anticipate that CRISPR Therapeutics AG will post -4.65 earnings per share for the current year.

Insider Buying and Selling

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of CRISPR Therapeutics stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider directly owned 19,357 shares of the company’s stock, valued at $1,076,636.34. The trade was a 16.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is currently owned by company insiders.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, signaling continued confidence in CRISPR Therapeutics’ development pipeline and long-term commercial potential. Piper Sandler Reaffirms Their Buy Rating on CRISPR Therapeutics AG
• Positive Sentiment: Bullish commentary highlighted potential CASGEVY sales growth and expansion into in vivo gene editing through CTX310, which could broaden CRSP’s future revenue opportunities if clinical and commercial milestones are achieved. CRISPR Strong Buy CASGEVY Sales Growth and In Vivo Expansion With CTX310
• Neutral Sentiment: Brookline Capital Markets made mixed revisions: its Q3 2026 loss estimate improved slightly to $1.30 per share from $1.31, while its FY2027 loss estimate improved to $4.51 from $5.05. However, the firm still expects CRSP to remain unprofitable in 2026 and 2027.
• Negative Sentiment: Brookline reduced its Q4 2026 EPS estimate to a loss of $1.87 from $1.69 and lowered its FY2026 estimate to a loss of $5.63 from $5.36. Both forecasts are weaker than the broader current-year consensus loss estimate of $4.90, potentially weighing on sentiment.
• Negative Sentiment: The same analyst modestly cut projected profits for FY2028, FY2029 and FY2030, suggesting a slightly less optimistic view of CRSP’s long-term earnings ramp. Despite those reductions, the estimates still imply a transition from losses to profitability beginning in FY2028.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.